Form 4: Phillip Frost and Frost Gamma Investments Trust Report OPKO Health Transaction

Phillip Frost, CEO and Chairman of OPKO Health, and Frost Gamma Investments Trust report a transaction involving 3.75% Convertible Notes due 2029 and common stock.

Summary

• Phillip Frost, CEO and Chairman of OPKO Health, and Frost Gamma Investments Trust filed a Form 4 with the SEC.
• The filing reports a transaction on March 4, 2025, involving 3.75% Convertible Notes due 2029 and common stock.
• Frost purchased $250,000 of the 3.75% Convertible Notes due 2029 at a price of $1.15.
• The notes are convertible into common stock at a conversion price of $1.15, subject to adjustments.
• The notes mature on January 15, 2029, and bear interest at 3.75% per annum, payable semi-annually.
• The filing also indicates Frost Gamma Investments Trust beneficially owns 38,558,000 shares of OPKO Health common stock.
• Dr. Frost disclaims beneficial ownership of these securities except to the extent of any pecuniary interest.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard SEC filing reporting a transaction. No explicit positive or negative indicators are present.

Future Outlook

The document does not contain specific forward-looking statements beyond the terms of the convertible notes.

Management Comments

• The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. The purchase of convertible notes could indicate a belief in the company's future prospects.

Key Dates